Given that our genomic data identified the upregulation of the SHH pathway to be a driver of MPNST-G1 tumors and our transcriptomic network analysis identified SMO inhibitors as a potential drug candidate, we hypothesized that sonidegib (SMO inhibitor) could provide a therapeutic benefit to MPNST lines with SHH pathway activation while not impacting the other cell line. This evidence concerns the gene SHH and malignant peripheral nerve sheath tumor.